Novel HER2 selective tyrosine kinase inhibitor, TAK‐165, inhibits bladder, kidney and androgen‐independent prostate cancer in vitro and in vivo

Purpose:  TAK‐165 is a new potent inhibitor of human epidermal growth factor receptor 2 (HER2) tyrosine kinase. Several reports suggest HER2 expression in bladder cancer, renal cell carcinoma (RCC) and androgen‐independent prostate cancer. We therefore investigated the antitumor effect of TAK‐165 on these urological cancer cells.

[1]  M. Brattain,et al.  Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. , 2005, Cancer research.

[2]  J. Montie.  Her-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. , 2005, The Journal of urology.

[3]  Y. Kajiyama,et al.  Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. , 2005, International journal of radiation oncology, biology, physics.

[4]  E. Crawford,et al.  The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial , 2004, The Prostate.

[5]  J. Lloreta,et al.  Her-2/neu Expression in Prostate Cancer , 2004, Clinical Cancer Research.

[6]  Tomoaki Tanaka,et al.  Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. , 2004, Oncology reports.

[7]  J. Doroshow,et al.  Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma , 2004, Cancer.

[8]  T. R. Griffiths,et al.  Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. , 2004, Urology.

[9]  M. Peyromaure,et al.  Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  L. Crinò,et al.  Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer , 2004, British Journal of Cancer.

[11]  Lesley Seymour,et al.  Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. , 2003, The Lancet. Oncology.

[12]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Hortobagyi,et al.  Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. , 2002, Cancer research.

[14]  John F Timms,et al.  Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells , 2002, Oncogene.

[15]  K. Wester,et al.  HER-2 - A Possible Target for Therapy of Metastatic Urinary Bladder Carcinoma , 2002, Acta oncologica.

[16]  M. Piccart-Gebhart.  Herceptin®: the future in adjuvant breast cancer therapy , 2001, Anti-cancer drugs.

[17]  S. Groshen,et al.  Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. , 2001, The Journal of urology.

[18]  M. Sliwkowski,et al.  Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. , 2001, Gastroenterology.

[19]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.